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Cancer cachexia is a complex, multifactorial syndrome 
involving progressive body weight loss, leading to loss of 
lean body mass and fat stores, combined with functional 
impairment, reduction in food intake, and altered metabo-
lism. Worldwide, more than 50% of advanced cancer 
patients suffer from cachexia, and it accounts for mortality 
in 10% of them.1,2 Cachexia progresses through different 
stages, initiated by less than 5% pretreatment body weight 
loss along with anorexia and various metabolic changes (ie, 
pre-cachexia stage), to more than 5% weight loss with sar-
copenia and systemic inflammation (ie, cachexia stage), 
and finally becoming unresponsive to anticancer treatment, 
with less than 3 months of expected patient survival (ie, 
refractory cachexia).3 Although established guidelines exist 
for nutrition management of cachexia (by various organiza-
tions) in cancer patients,4-6 these guidelines are not adopted 
by the majority of the Indian public hospitals in view of a 
shortage of clinical nutritionists as part of the cancer 
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Abstract
Purpose. Advanced cancer patients with disease progression develop cachexia. Nevertheless, cancer patients at nutritional 
risk have shown improved body weight and quality of life with oral nutritional supplements. Method. This was a randomized 
controlled trial in adult female cancer patients (n = 63) attending palliative clinics, with symptoms of cachexia. Eligible 
patients were randomly distributed into control (n = 33) and intervention (n = 30) groups. Both groups were provided 
with nutritional and physical activity counseling, but the intervention group received an additional 100 g of Improved 
Atta (IAtta) for 6 months daily consumption. This study was designed to assess the efficacy of IAtta (with counseling) in 
enhancing the health status of cachexic patients. Anthropometric measurements, dietary intake, physical activity level and 
quality of life parameters were assessed at baseline, after 3 months, and at the end of 6 months. Results. Patients in the 
control group (n = 15) had significantly decreased body weight (P = .003), mid–upper-arm circumference (P = .002), and 
body fat (P = .002) by the end of intervention. A trend of body weight gain in the intervention group (n = 17; P = .08) and 
significant increase of body fat (P = .002) was observed; moreover, patients reported a significant improvement in fatigue 
(P = .002) and appetite scores (P = .006) under quality-of-life domains at the end of intervention. Conclusions. Embedding a 
nutrition-sensitive intervention ( IAtta ) within Indian palliative care therapy may improve quality of life and stabilize body 
weight in cancer cachexia patients.
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management team. Nutritional management remains a 
lacuna in their care.
The accessibility to reliable cancer treatment and pallia-
tive care is very limited for most Indians. The number of 
oncologists and palliative care health workers in India is 
low when compared with the developed world, in spite of 
the high incidence of cancer.7 The central and state govern-
ments spend less than 1.5% of their gross domestic products 
on public health care. Development of better infrastructure 
and management in cancer care will be difficult if the cen-
tral and state governments do not increase the budget and 
allowances allocated for public health.8 Strategies need to 
be developed by channeling the available resources and 
keeping in mind the social norms for patient-centered pal-
liative care in India. International guidelines need to be tai-
lored to address cancer patient care in the Indian public 
health setting.7
In spite of increasing awareness and availability of health 
care facilities for palliative care, the role of nutrition is not 
being emphasized. Palliative care for cachexia patients should 
involve a multimodal treatment approach, which includes not 
only symptom management, but also nutritional supplementa-
tion to correct the energy deficit and physical activity to 
reduce muscle atrophy.4 Advanced cancer patients have 
shown increased lean body mass and better quality of life 
when their diets are supplemented with oral nutritional sup-
plements (ONSs) and/or they are provided with nutritional 
counseling.9,10 Moreover, dietary counseling has enhanced 
energy and protein intake and quality of life, reduced radio-
therapy toxicity complications, and lowered mortality among 
advanced cancer patients.11,12 It has been documented that the 
nutritional intake of cancer cachexia patients is calorie defi-
cient, and they suffer from micronutrient deficiencies.13-17 In 
the absence of energy-dense nutrient-rich supplements in their 
diets, the nutritional requirements of these patients are not 
met, and this puts them in jeopardy.18
ONS is a synthetic energy and protein-dense formula, 
which aids in patient health status improvement and is 
widely available in the Indian market. However, this 
remains unaffordable or unavailable for many in the Indian 
community. Also, Indians like home cooked food, which is 
more acceptable compared with packed or refined food 
items.19 There is a need to develop a natural nutritional sup-
plement meal that can be prepared with minimal training at 
home using locally available sustainable ingredients. Such 
a meal can help correct nutritional deficits and improve 
treatment outcomes among poor cancer patients. At the 
present time, research is moving toward designing a 
nutrition-specific optimum mix of foods to target malnutri-
tion among poor populations by addressing food security as 
well—namely, nutrition-sensitive interventions.20 Nutrition-
sensitive intervention meals will address global malnutri-
tion as well as support the development of small- and 
medium-sized enterprises.20
In India, the traditional flat bread chapati is made of 
whole wheat flour (called atta) and, along with curry, is 
consumed daily by approximately 50% of urban and rural 
people.21 We, therefore, developed a nutritious flour mix 
using locally available and acceptable ingredients, called 
Improved Atta (IAtta). The purpose of this study was to 
determine whether this nutrition-sensitive intervention 
(along with dietary counseling) improves anthropometric 
indicators and quality of life in free-living cancer cachexic 
patients.
We hypothesize that IAtta supplementation along with 
nutritional counseling can improve cancer cachexic patients’ 
anthropometric status and quality of life.
Methods
The study was carried out at Dr BRA Institute Rotary 
Centre Hospital, All India Institute of Medical Sciences 
(AIIMS), New Delhi, India between December 2013 and 
August 2014. This centre provides comprehensive pallia-
tive care to cancer patients. This study was approved by 
the ethics committees of the University of Westminster 
(Approval No.: 12_13_11) and AIIMS (IEC/NP-79/2013) 
prior to recruitment. The study was carried out in accor-
dance with the guidelines of the Indian Council of 
Medical Research and Helsinki Declaration. It is regis-
tered on http://www.clinicaltrials.gov vide, identifier no. 
NCT02350855.
In this prospective randomized controlled intervention, 
we recruited female free-living cancer cachexic patients 
who were attending the palliative care clinic for symptom 
management. A total of 123 adult female patients with 
advanced cancer were screened for eligibility. Patients 
with weight loss of more than 5% from pretreatment 
weight, body mass index less than 20 kg/m2 along with 
hemoglobin level less than 12 g/dL, and energy intake of 
less than 1500 kcal/d were considered eligible for partici-
pation. Patients with gastrointestinal tract disorders, on 
anabolic steroids, taking synthetic ONSs, and with life 
expectancy of less than 3 months were excluded from par-
ticipation. The study’s protocol and patients’ eligibility 
criteria have been published earlier.10 Eligible patients 
were asked for consent and enrolled in the study. They 
were allocated study codes, and a randomization sheet was 
generated by using nQuery software (7.0 version) by RG. 
The patients were enrolled by NK and then allocated into 
2 groups—intervention group (30 patients) and control 
group (33 patients)—by RG using simple randomization 
procedures (Figure 1). Both groups were provided with 
nutritional counseling (by NK), but the intervention group 
also received 100 g of IAtta (by RG), to be consumed in 
addition to their daily dietary intake for 6 months. The 
patients in control groups were unaware of the IAtta inter-
vention in the other group.
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Intervention
In both groups, all patients received 30 minutes of dietary 
counseling per visit by a qualified nutritionist. Patients were 
advised to increase the frequency of homemade meals, and 
the consumption of energy- and protein-dense food prod-
ucts was encouraged during these sessions.
Patients in the intervention group collected 14 packets of 
100 g of IAtta every fortnight during their appointments, 
whereas the control patients were advised with respect to 
their dietary habits at every clinic visit (twice a month). 
Intervention group patients were advised to consume the 
whole IAtta pack in addition to their daily diet. Each 100 g 
pack of IAtta contained a mixture of roasted bengal gram 
flour, roasted barley flour, roasted soybean flour, flaxseed 
powder, and dried Amaranthus spinosus powder (Table 1). 
All ingredients included were in roasted and dried form to 
eliminate microorganism growth and ensure longer shelf 
life. IAtta was prepared in the hospital kitchen every eve-
ning before the patients’ appointment the next day. Utensils 
used during preparation and ingredient mixing were prop-
erly washed and disinfected before every use. Kitchen sur-
faces in contact with food were cleaned at initiation, and 
adequate personal hygiene was ensured at all stages of IAtta 
preparation. It was double packed using food grade plastic 
bags to eliminate moisture and pathogens. Each pack was 
labeled with use by date and batch number. The caregiver 
was advised to make unleavened flat breads (chapatis) by 
adding spices from the dispensed IAtta pack and to discard 
leftover supplement at the end of the day. On average 3 flat 
breads could be prepared from each pack, which provides 
approximately 400 kcal. Each 400 kcal consists of 50% 
daily protein requirement, 75% daily fat requirement, and 
30% to 50% of iron, calcium, and vitamin A as part of an 
Figure 1. Study consort diagram.
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Indian sedentary woman’s recommended dietary allow-
ance.22 Adherence to IAtta consumption was assessed by 
self-report of the patient (and/or caregiver), and a manual 
record of the number of packets dispensed at each visit was 
maintained. Before the start of follow-up counseling ses-
sions, patients were first interviewed about the number of 
packets left and accordingly given fresh packs to consume.
Depending on the physical status of the patients, low lev-
els of physical activity (walking and/or stairs) and partici-
pation in household activities was encouraged during 
counseling sessions.
Data Collection
Anthropometric measures, nutritional status, physical activ-
ity levels, and quality of life estimation were assessed at 
baseline, after 3 months, and at 6 months of recruitment for 
patients in both the groups by NK.
Anthropometric Parameters. Body weight was assessed 
using Tanita BC-545N segmental composition monitor 
(Tanita Corporation, Tokyo, Japan). Mid–upper -arm cir-
cumference (MUAC) was measured using a nonstretchable 
measuring tape. Four site skin fold thickness (SFT; ie, tri-
ceps, biceps, subscapular and suprailiac) was measured to 
the nearest 0.2 mm (Harpenden Skinfold Caliper, 0120, 
Baty International, West Sussex, England). The sum of 4 
skinfolds was used to calculate body density. Body fat per-
centage was calculated using the Siri equation.23 All 
anthropometric measurements were taken by the same 
trained investigator throughout the study.
Nutritional Status Parameters. Dietary history was obtained 
during one-on-one interview sessions between the nutri-
tionist and the patient. Two-day 24-hour dietary recall data 
were recorded using sample vessels of different sizes for 
portion size estimation. Additionally, the Indian Migrant 
Study Food Frequency Questionnaire (IMS-FFQ) consist-
ing of 184 commonly consumed food items and validated 
among the rural and urban Indian population was used.24 
Patients’ daily energy, carbohydrate, protein, and fat intake 
were calculated using IMS-FFQ and dietary recall data. 
Dietary data were analyzed using DietCal software (Dietary 
Assessment and Planning software based on the book Nutri-
tive Value of Indian Foods).25 The Patient Generated Sub-
jective Global Assessment (PG-SGA) questionnaire helped 
monitor the deterioration or improvement of patients’ nutri-
tional status throughout the study. PG-SGA has been rec-
ommended as the nutrition assessment tool for cancer 
patients by the Oncology Nutrition Dietetic practice group 
of the American Dietetic Association.26
Physical Activity Level. The Indian Migrant Study Physical 
Activity Questionnaire (IMS-PAQ) was used to assess 
patients’ physical activity throughout the day.27 Patients 
reported every activity performed along with the average 
amount of time spent for each activity. Metabolic equiva-
lent unit (MET) was assigned to each activity performed 
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according to the Compendium of Physical activity.28 Thus, 
patients’ total daily energy expenditure was estimated.
Quality-of-Life Assessment. The EORTC-QLQ-C30 question-
naire, a validated tool, was used to analyze patients’ quality 
of life.29 A translated version in Hindi was available from 
the official website. The questionnaire consisted of 30 ques-
tions, which were divided into 5 functional scales— 
physical, role, cognitive, emotional, and social—8 symp-
tom scales—fatigue, nausea and vomiting, pain, dyspnea, 
sleep disturbance, loss of appetite, constipation, and diar-
rhea— and global health and financial status. A score was 
calculated for all the 15 domains using the scoring manual.
Statistical Methods
Sample size calculations have been published earlier.8 The 
sample size for the pilot study was calculated considering 
similar baseline weight in the 2 groups. After 6 months of 
intervention, we expected a difference of approximately 10 kg 
of weight between the intervention group and control group. 
The study sample size was calculated as 72, with 36 patients 
per group, in order to study the impact of intervention. This 
sample size is chosen based on a CI (power) of 80% for allow-
able sample error (precision limit) of 5%. But because of a 
low recruitment rate, the study commenced with a total of 63 
patients. All statistical analyses were done using SPSS soft-
ware (version 20.0, SPSS Inc, Chicago, IL). Data were ana-
lyzed using repeated-measures ANOVA and the Friedman test 
followed by Bonferroni correction for multicomparisons to 
determine the changes within the groups at different time 
points. The Student t-test and Wilcoxon signed-rank test were 
conducted on the variables to assess the difference between 
intervention and control groups. Baseline parameters—body 
weight, body fat, MUAC, energy intake, physical activity 
level, global health quality of life, and fatigue domain—were 
adjusted to observe the overall difference between the groups 
using a generalized estimating equation. A P value ≤.05 was 
considered statistically significant.
The primary end points of this study were to improve 
patients’ anthropometric status and quality of life. 
Maintaining physical activity, nutritional status, and bio-
chemical parameter assessments were among the secondary 
end points for this study.
Results
Patients’ baseline characteristics and tumor site have been 
detailed in Tables 2 and 3, respectively. Out of the 63 
patients recruited for the study, 51% completed the inter-
vention. There were no demographic or clinical differences 
among the patients who dropped out compared with the 
ones who finished the study. Data analysis was blinded 
because all data were collected using patient codes.
Anthropometric Results
Patients in the intervention group had gained body weight, 
but this was not statistically significant (P = .081), whereas 
patients in the control group showed statistically signifi-
cantly reduced body weight (P = .003) and MUAC (P = 
.006) at the end of 6 months (Figures 2 and 3). Body fat 
increased significantly in the intervention group (P = .002) 
and decreased significantly in the control group (P = .032) 
at the end of the 6-month intervention as compared with 
baseline (Figure 4). Adjusted analysis revealed significant 
difference in percentage body fat among the groups (P 
value = .001).
Dietary Intake and Nutritional Status Results
At the end of 6 months, a significant increase in energy 
intake (P = .001) and macronutrient intake—that is, carbo-
hydrate (P = .001), protein (P = .001), and fat (P = .006)—
was observed in the intervention group (Table 4). Using the 
FFQ, intervention group patients also showed a statistically 
significant increase in energy intake (P = .006). The 
PG-SGA score for the intervention group improved at the 
end of the 6-month study (from baseline 7.8 ± 2.2 to 6.5 ± 
3.1 at 6 months) but was not statistically significant (P = 
.735), whereas for the control group, the score did not 
change (from baseline 9.4 ± 2.6 to 9.5 ± 2.4 at 6 months, 
P = .863). On adjusting the baseline parameters there was a 
significant change in energy intake (P = .004, by dietary 
recall) and PG-SGA score (P < .001) during intervention.
Physical Activity Results
Physical activity recall (Table 5) showed significantly 
reduced activity from 30.7 ± 2.7 METs at baseline to 28.0 ± 
2.5 METs at 6 months (P = .004) among the control group, 
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whereas the intervention group of patients maintained their 
physical activity levels throughout the study from 33.6 ± 3.9 
METs at baseline to 31.9 ± 2.7 METs at 6 months (P = .274).
Quality-of-Life Results
Patients consuming IAtta showed significant improvement 
at 6 months in certain domains of quality of life (Table 6), 
such as fatigue (P = .002) and appetite loss (P = .006). A 
significant decrease in quality of life domains of global 
health status (P = .018) and social functioning (P = .004) 
was observed among control group patients at 6 months. 
Both the groups reported a significant improvement in pain 
at the end of 6 months (P = .012 in the intervention group, 
and P = .029 in control group). At the end of 6 months of the 
study period, there were significant differences (P < .001) 
between the intervention and control group patients in 
global health status, social functioning, appetite, and fatigue 
domains. When global health status and fatigue score were 
adjusted at baseline, there was a significant difference in 
these parameters during the intervention at 3 and 6 months 
(P < .001).
The mean consumption of IAtta flour (as chapatis) 
among the patients who finished the study was 45 ± 11.26 
g/d, providing them 180 kcal/d, consisting of 20 g of carbo-
hydrate, 11 g of protein, and 6 g of fat (see Table 4 for more 
details). None of the patients reported any side effects of 
consuming IAtta chapatis.
Table 3. Baseline Characteristics of All Patients.a
Baseline Parameters Intervention Group (n = 30) Control Group (n = 33) P Value
Age (years) 44.0 ± 13.2 47.8 ± 14.7 .284
Weight (kg) 39.7 ± 5.7 41.1 ± 7.3 .402
MUAC (cm) 20.8 ± 2.1 22.2 ± 2.4 .49
Body fat (%) 20.5 ± 5.2 25.4 ± 6.5 .012b
Energy intake (kcal) 947.4 ± 327.9 756.7 ± 364.2 .033b
Protein intake (g) 30.3 ± 12.0 23.3 ± 12.6 .03b
Fat intake (g) 28.1±13.1 24.9 ± 14.9 .375
PG-SGA score 7.8 ± 2.2 9.4 ± 2.6 .010b
Global Health Status score (QoL) 66.7 (16.7, 83.3) 50 (8.3, 100) .026b
Fatigue score (QoL) 88.9 (0, 100) 100 (0, 100) .05b
Appetite loss score (QoL) 66.7 (0, 100) 100 (0, 100) .047b
Abbreviations: MUAC, mid–upper-arm circumference; PG-SGA, Patient-Generated Subjective Global Assessment; QoL, quality of life.
aData presented as mean ± SD or median (range).
bDenotes P < .05.
Figure 2. The body weight of patients at baseline, mid-
intervention, and post-intervention.
* Data presented as mean ± SD; P value ≤.05 was considered statistically 
significant at 95% CI.
Figure 3. The mid–upper-arm circumference (MUAC) of 
patients at baseline, mid -intervention, and post- intervention.
* Data presented as mean ± SD; P value ≤.05 was considered statistically 
significant at 95% CI.
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Discussion
In the current study, IAtta meal supplementation along with 
nutritional counseling in female patients with advanced 
cancer receiving palliative care improved their quality of 
life and stabilized body weight.
Patients consuming IAtta for the duration of 6 months 
showed clinically increased body weight (increase in body 
weight by 2.5%; P = .081) and body fat percentage 
(increased by 3.7%; P = .002) in contrast to the control 
group, who showed significantly reduced body weight 
(decreased by 8.71%; P = .003) and body fat percentage 
(decreased by 5.2%; P = .032). The increase in body fat 
would be desirable in cachexic patients. Also, in this study, 
patients in the control group had a reduction of 14.4% of 
MUAC (P = .002) at 6 months as compared with baseline. 
Low MUAC (between 22 and 24 cm) among adults has 
been associated with several adverse health outcomes,30 and 
all current study patients (in both groups) at baseline had 
MUAC less than 23 mm, which is associated with a higher 
health risk. A recent observational study has concluded that 
significant weight loss in patients with advanced cancer is 
associated with reduced survival.31 Weight-losing cancer 
patients have shown reduced mobility, immunity, and che-
motherapy endurance.32,33 A similar pattern has been docu-
mented earlier in cancer patients when their diets were 
supplemented with ONS.34,35 However, a recent meta- 
analysis by Baldwin et al,9 which included 13 RCTs involv-
ing malnourished cancer patients, concluded that there was 
no statistically significant relationship between synthetic 
ONS intervention and body weight gain. The baseline char-
acteristic of most of the anthropometric indicators (body 
weight and MUAC) was similar in both the patient groups 
(except body fat); therefore, we can argue that IAtta has a 
significant impact on patients’ health status (Table 3).
The energy intake of all study patients at baseline was 
lower than the Indian adult female RDA (<1900 kcal, 
Table 2).22 Research has shown that with disease progres-
sion, basal metabolic rate increases.36,37 Therefore, the 
energy intake of patients should be higher in order to main-
tain their nutritional status. A significant difference was 
observed in the baseline energy and protein intake of both 
groups of patients. Dietary intake was assessed using self-
reported questionnaires. Data collected from these tools are 
subject to reporting errors.38 Whereas patients in the control 
group reported lower baseline energy (756.7 ± 364.2 kcal) 
and protein (23.2 ± 12.6 g) intake, their body fat was 25.4% 
± 6.5 % higher compared with that of the intervention group 
(20.5% ± 5.2%). Also, the baseline body weight and MUAC 
were comparable between the 2 groups. The intervention 
patients reported a significant increase in their daily energy, 
protein, and fat intake at the end of the intervention, which 
was greater than 40 g of IAtta average consumption. The 
key reason could be a significant improvement in appetite, 
reduced fatigue (QoL domain assessed in Table 6), and 
maintenance of normal physical activity (Table 5) along 
with cumulative positive effect of IAtta natural ingredients. 
IAtta possibly had a positive impact on their health status 
and well-being (Table 6), despite progression of the neo-
plastic disease, which improved their appetite. There was 
no significant change in the PG-SGA score of the interven-
tion group patients at the end of intervention, which is simi-
lar to the pattern observed earlier in advanced colorectal 
cancer patients receiving ONS supplementation.39
In a recent study on weight-losing advanced cancer 
patients, it was shown that along with weight loss and lower 
MUAC, these patients had reduced functional abilities.40 In 
advanced lung cancer patients, it has been suggested that an 
exercise and nutrition intervention may have a positive 
impact on unintentional weight loss and physical function.41 
The current study results are in line with those of the above 
studies because patients consuming IAtta maintained their 
body weight as well as physical activity levels. Also, 
patients losing body weight (control group) showed reduced 
physical activity levels (baseline, 30.7 ± 2.7 METs; 6 
months, 28.0 ± 2.5 METs) at the end of the study period. 
There is a statistically significant positive correlation 
between physical activity and quality of life.42 Though both 
the groups received physical activity counseling in the cur-
rent study, the key factor for maintained physical activity in 
the intervention group could be consumption of nutrient-
rich IAtta, compensating for the macronutrient and micro-
nutrient deficits in their diets.
The global health status and emotional functioning 
domain under the functional scale and loss of appetite and 
dyspnea domains under the symptom scale showed associa-
tion with ONS intake in malnourished cancer patients.9 
Figure 4. The body fat percentage of patients at baseline, mid-
intervention, and post -intervention.
* Data presented as mean ± SD; P value ≤.05 was considered statistically 
significant at 95% CI.
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Observations on malnourished cancer patients suggest a 
decline in quality of life with body weight loss.40,43 A simi-
lar trend was observed in this study: patients consuming 
IAtta exhibited improvement in fatigue and appetite loss 
domains, whereas weight-losing control group patients 
declined under the global health status (P = .018) and social 
functioning (P = .004) domains. Patients in the intervention 
group received counseling and IAtta, which could have 
helped in reducing fatigue and improving appetite levels.
Limitations
One weakness of the study was the patient drop-out rate: as 
result of progressive disease, 29% were unable to travel to 
the hospital, and 21% had an early death. Attrition rate as 
high as 45% has been reported in palliative oncology trials 
because of clinical deterioration and morbidity among 
patients.44,45 Patients belonging to all socioeconomic strata 
were included in the study, and therefore, our population 
was mixed. We were not able to observe a specific pattern in 
their food habits throughout the intervention. Therefore, 
dietary intake was significantly different between groups at 
baseline. This could not be a bias because concealment and 
randomization was practiced throughout the study. A homo-
geneous group of female cancer patients was recruited for 
the study because there were no existing data available to 
report impact of natural food supplementation on patient 
nutrition status in the palliative care setting. Research is 
needed to study the impact of IAtta supplementation in 
organ-specific cancer palliative care patients. Like other 
supplementation studies in the past on advanced cancer 
patients, the intervention group patients were unable to con-
sume the advised amount of IAtta (compliance rate of 
41%).39,46,47 The key reasons reported were anorexia, appe-
tite loss, mouth sores, and constipation as a result of pallia-
tive chemoradiotherapy (for symptom management), 
toxicity complications, and medications. The patients 
recruited for this study were free-living and consuming the 
IAtta meal at home with their family. The subsequent body 
weight gain of 2.5% in the intervention group patients proves 
Table 5. Physical Activity Levels of Patients During Baseline, Follow-up at 3 Months, and Post intervention.a
Physical Activity (METs) Measurement Intervals Intervention Group Control Group P Value
Baseline 33.6 ± 3.9 (n = 30) 30.7 ± 2.7 (n = 33) .01b
 3-Month intervention 33.2 ± 4.1 (n = 21) 28.4 ± 2.5 (n = 18) .007b
 6-Month intervention 31.9 ± 2.7 (n = 17) 28.0 ± 2.5 (n = 15) <.001b
 P Value (overall) .274 .004b  
aData presented as mean ± SD.
bP value ≤.05 was considered statistically significant at 95% CI.
Table 4. Dietary Intake (according to 2-Day Dietary Recall) of Patients During Baseline, Follow-up at 3 Months and Post 
intervention.a
Nutrient Measurement Intervals Intervention Group Control Group P Value
Energy by dietary recall 
(kcal) 
 
Baseline 947.4 ± 327.9 (n = 30) 756.7 ± 364.2 (n = 33) .033b
3-Month intervention 1284.4 ± 510.2 (n = 21) 689.0 ± 388.5 (n = 18) .003b
6-Month intervention 1485.3 ± 477.4 (n = 17) 803.0 ± 525.0 (n = 15) .001b
 P value (overall) .001b .519  




Baseline 142.7 ± 50.5 (n = 30) 109.1 ± 51.0 (n = 33) .011b
3-Month intervention 178.2 ± 69.7 (n = 21) 100.1 ± 46.3 (n = 18) <.001b
6-Month intervention 226.9 ± 81.1 (n = 17) 123.0 ± 63.0 (n = 15) <.001b
P value (overall) .001 .519  
Protein by dietary recall (g) 
 
 
Baseline 30.3 ± 12.0 (n = 30) 23.2 ± 12.6 (n = 33) .03b
3-Month intervention 45.2 ± 16.1 (n = 21) 22.2 ± 14.4 (n = 18) <.001b
6-Month intervention 49.5 ± 16.9 (n = 17) 23.2 ± 15.6 (n = 15) <.001b
P value (overall) .001b .593  
Fat by dietary recall (g) Baseline 28.1 ± 13.1 (n = 30) 24.9 ± 14.9 (n = 33) .375
 3-Month intervention 43.5 ± 21.0 (n = 21) 21.7 ± 17.4 (n = 18) .001b
 6-Month intervention 42.8 ± 19.2 (n = 17) 25.0 ± 28.6 (n = 15) .046b
 P value (overall) .006b .881  
aData presented as mean ± SD.
bP value ≤.05 was considered statistically significant at 95% CI.
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that they were consuming the meal themselves and not shar-
ing it. Another weakness of this study was the inability to 
assess patients’ fat-free mass. Though a Tanita segmental 
body composition machine was used to determine muscle 
mass, it was a challenge to maintain patient hydration status 
and environmental conditions during each visit; therefore, 
the variable was excluded. The machine works on the prin-
ciple of bioelectric impedance and values depend on patient 
hydration status.48 Total body water content was comparable 
between patient groups at baseline, mid-intervention, and 
post-intervention (P = .453, P = .234, and P = .727, respec-
tively), as measured by the Tanita segmental body composi-
tion machine. Therefore, the change in SFT was attributed to 
nutritional intake and not to lymphadenopathy, ascites, and 
hydration status in the intervention group patients. The 
observed reduction in MUAC and bicep, tricep, suprailliac, 
and suprascapular SFT among control group patients is a 
clear indicator of loss of skeletal muscle mass in cachexic 
patients, implying poor prognosis.49
Conclusion
Nutrition is an essential component of a multimodal 
cachexia treatment, and it is not feasible to increase or 
maintain patients’ body weight if nutritional demands are 
neglected. Embedding nutrition supplementation within 
the palliative care therapy may improve quality of life and 
stabilize body weight in cancer cachexia patients. A large-
scale intervention to further establish the effectiveness of 
IAtta on patients’ quality of life and their health status is 
highly desirable.
Acknowledgments
The research team gratefully acknowledges the assistance of doc-
tors and hospital support staff at AIIMS, New Delhi, India. Special 
thanks to Dr R. M. Pandey and Vineet Kamal at the Department of 
Biostatistics, AIIMS, for their guidance throughout the project. 
We thank the administrative team at Indian Council of Medical 
Research for their guidance in obtaining ethical clearance from the 
Indian Health Ministry. A special thanks to all the study patients 
for their cooperation and time throughout the study.
Authors’ Note
This study is registered on http://www.clinicaltrials.gov vide, 
identifier no. NCT02350855.
Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect 
to the research, authorship, and/or publication of this article.
Funding
The author(s) disclosed receipt of the following financial support 
for the research, authorship, and/or publication of this article: The 
study was self-funded by NK (study investigator).
Table 6. Selected QoL Domain Scores of Patients During Baseline, Follow-up at 3 Months, and Post-intervention.a
Domain Measurement Intervals Intervention Group Control Group P Value
Global health status Baseline 66.7 (16.7, 83.3), n = 30 50 (8.3, 100), n = 33 .026b
 3-Month intervention 66.6 (16.7, 83.3), n = 21 41.7 (0, 66.6), n = 18 .001b
 6-Month intervention 66.7 (16.7, 83.3), n = 17 16.7 (0, 50), n = 15 <.001b
 P Value (overall) .985 .018b  
Social functioning Baseline 66.7 (0, 100), n = 30 50 (0, 100), n = 33 .02b
 3-Month intervention 66.6 (0, 100), n = 21 0 (0, 100), n = 18 .002b
 6-Month intervention 66.7 (16.7, 100), n = 17 0 (0, 100), n = 15 <.001b
 P value (overall) 0.802 0.004b  
Fatigue Baseline 88.9 (0, 100), n = 30 100 (0, 100), n = 33 .05b
 3-Month intervention 55.5 (0, 100), n = 21 100 (66.7, 100), n = 18 <.001b
 6-Month intervention 66.7 (0, 100), n = 17 100 (66.7, 100), n = 15 <.001b
 P value (overall) .002b .819  
Pain Baseline 75.0 (0, 100), n = 30 100 (16.67, 100), n = 33 .017b
 3-Month intervention 33.3 (0, 100), n = 21 100 (16.7, 100), n = 18 <.001b
 6-Month intervention 16.7 (0, 100), n = 17 33.3 (0, 100), n = 15 .129
 P value (overall) .012b .029b  
Appetite loss Baseline 66.7 (0, 100), n = 30 100 (0, 100), n = 33 .047b
 3-Month intervention 0 (0, 100), n = 21 100 (0, 100), n = 18 <.001b
 6-Month intervention 0 (0, 100), n = 17 100 (0, 100), n = 15 .001b
 P value (overall) .006b .676  
Abbreviation: QoL, quality of life.
aData presented as median (range).
bA P value ≤.05 was considered statistically significant at a 95% CI.
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